Cargando…

Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series

OBJECTIVE: Chemotherapy regimens containing rituximab (RTX) have been extensively used to treat diffuse large B cell lymphoma (DLBCL). However, data looking at long-term safety of DLBCL patients with hepatitis B-related cirrhosis are still lacking. This study aims to report the safety and outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zaiwei, Ma, Yi, Jiang, Dan, Zhao, Rongsheng, Dong, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195509/ https://www.ncbi.nlm.nih.gov/pubmed/35712098 http://dx.doi.org/10.3389/fmed.2022.890339

Ejemplares similares

Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
por: Ha, Hyerim, et al.
Publicado: (2016)

DLBCL developed into fatal liver failure during rituximab-containing chemotherapy
por: Shimazu, Yutaka, et al.
Publicado: (2019)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Risk factors for hepatic hydrothorax in patients with cirrhosis: a clinical retrospective study
por: Bai, Xue, et al.
Publicado: (2023)

Toward therapeutic drug monitoring of citalopram in depression? Insights from a systematic review
por: Xu, Na, et al.
Publicado: (2023)

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021)

Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)
por: Varley, Cara D., et al.
Publicado: (2021)

Metabolomic Signatures of Autoimmune Hepatitis in the Development of Cirrhosis
por: Li, Shan-shan, et al.
Publicado: (2021)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

The impact and role of hepatic hydrothorax in the prognosis of patients with decompensated cirrhosis: A retrospective propensity score-matched study
por: Ma, Bo, et al.
Publicado: (2022)

Case report: Hepatic tuberculosis mimicking hepatocellular carcinoma in a patient with cirrhosis induced by hepatitis B virus
por: Hu, Na, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis
por: Shah, Islam, et al.
Publicado: (2021)

Insulin-like growth factor 1 predicts decompensation and long-term prognosis in patients with compensated cirrhosis
por: Saeki, Chisato, et al.
Publicado: (2023)

Prognostic Value of Serum Exosomal AHCY Expression in Hepatitis B-Induced Liver Cirrhosis
por: Tong, Ling, et al.
Publicado: (2021)

Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China
por: Rui, Mingjun, et al.
Publicado: (2021)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases
por: Memon, Anza B., et al.
Publicado: (2018)

Pan-Cancer Analysis of Voltage-Dependent Anion Channel (VDAC1) as a Cancer Therapeutic Target or Diagnostic Biomarker
por: Wang, Zhitong, et al.
Publicado: (2022)

Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria
por: Dimitrova, Maria, et al.
Publicado: (2017)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

Efficacy and Safety of Treatment With Ferric Carboxymaltose in Patients With Cirrhosis and Gastrointestinal Bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2020)

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey
por: Hu, Yang, et al.
Publicado: (2022)

Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver
por: Roni, D. Ajith, et al.
Publicado: (2013)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
por: Ju, Young-Cheol, et al.
Publicado: (2018)

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
por: Bartlett, N. L., et al.
Publicado: (2022)

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes
por: Liu, Shu, et al.
Publicado: (2021)

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017)

Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
por: Canales Albendea, Miguel Á., et al.
Publicado: (2023)

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
por: Song, Zaiwei, et al.
Publicado: (2022)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

The Impact of Portal Vein Thrombosis on the Prognosis of Patients With Cirrhosis: A Retrospective Propensity-Score Matched Study
por: Chen, Zhiji, et al.
Publicado: (2021)

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia
por: Nakagawa, Noriharu, et al.
Publicado: (2022)

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Liver Stiffness Is a Predictor of Rebleeding in Patients With Hepatitis B-Related Cirrhosis: A Real-World Cohort Study
por: Liu, Linxiang, et al.
Publicado: (2021)

Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study
por: Lu, Xiya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v61a0kbcro0skna5vmn0hgbbqn